PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

mTOR is an important therapeutic target in many types of cancers. In melanoma, the mTOR nonsynonymous mutation rate is up to 10.4%. However, mTOR inhibitors have shown limited effects in clinical trials of melanoma. Because mTOR mutations are distributed, not selecting patients with specific mTOR mu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Wu, Xiaowen, Yu, Jiayi, Yan, Junya, Dai, Jie, Si, Lu, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Ma, Meng, Tang, Huan, Xu, Tianxiao, Yu, Huan, Kong, Yan, Guo, Jun
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989792/
https://ncbi.nlm.nih.gov/pubmed/29708815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1435221
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars